pyrimethamine has been researched along with Brain Inflammation in 71 studies
Maloprim: contains above 2 cpds
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this international, noncomparative, randomized phase II trial, we evaluated the effectiveness and tolerance of atovaquone suspension (1500 mg orally twice daily) plus either pyrimethamine (75 mg per day after a 200-mg loading dose) or sulfadiazine (1500 mg 4 times daily) as treatment for acute disease (for 6 weeks) and as maintenance therapy (for 42 weeks) for toxoplasmic encephalitis (TE) in patients infected with human immunodeficiency virus." | 9.10 | Randomized phase II trial of atovaquone with pyrimethamine or sulfadiazine for treatment of toxoplasmic encephalitis in patients with acquired immunodeficiency syndrome: ACTG 237/ANRS 039 Study. AIDS Clinical Trials Group 237/Agence Nationale de Recherche ( Andersen, J; Bosler, EM; Chirgwin, K; Hafner, R; Jayaweera, DT; Leport, C; Luft, BJ; McAuliffe, V; Morlat, P; Rajicic, N; Remington, J; Roque, C; Vilde, JL, 2002) |
| "To assess the safety, tolerance and activity of increasing doses of azithromycin in combination with pyrimethamine for the treatment of toxoplasmic encephalitis (TE) in patients with AIDS." | 9.09 | Dose-escalation, phase I/II study of azithromycin and pyrimethamine for the treatment of toxoplasmic encephalitis in AIDS. ( Bosler, EM; Farthing, C; Hafner, R; Harris, C; Holden-Wiltse, J; Jacobson, JM; Jayaweera, DT; Luft, BJ; Remington, J; Roque, C, 2001) |
| "An open, randomised, multicentre trial was conducted to evaluate the efficacy of thrice-weekly versus daily therapy with sulfadiazine-pyrimethamine in the prevention of relapses of toxoplasmic encephalitis in HIV-infected patients." | 9.09 | Thrice-weekly sulfadiazine-pyrimethamine for maintenance therapy of toxoplasmic encephalitis in HIV-infected patients. Spanish Toxoplasmosis Study Group. ( Arrizabalaga, J; Cosin, J; Cruceta, A; Domingo, P; Fariñas, MC; Ferrer, E; Gatell, JM; Gudiol, F; Knobel, H; Leyes, M; Martínez-Lacasa, J; Miró, JM; Podzamczer, D; Polo, R; Ramón, JM; Ribera, E; Sirera, G, 2000) |
| "To evaluate combined prophylaxis for Pneumocystis carinii pneumonia (PCP) and toxoplasmic encephalitis, 533 patients with symptomatic human immunodeficiency virus infection and/or CD4 lymphocyte counts of < 200/microL were randomized to receive dapsone/pyrimethamine (200/75 mg once weekly) or aerosolized pentamidine (300 mg every 4 weeks)." | 9.08 | Once-weekly administration of dapsone/pyrimethamine vs. aerosolized pentamidine as combined prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus-infected patients. ( Heald, A; Hirschel, B; Iten, A; Lazzarin, A; Oertle, D; Opravil, M; Pechère, M; Praz, G; Rüttimann, S; von Overbeck, J, 1995) |
| "The aim of the present pilot study was to compare the efficacy and safety of trimethoprim (TMP) and sulfamethoxazole (SMX) with those of the standard therapy pyrimethamine (P)-sulfadiazine (S) for the treatment of toxoplasmic encephalitis in patients with AIDS." | 9.08 | Randomized trial of trimethoprim-sulfamethoxazole versus pyrimethamine-sulfadiazine for therapy of toxoplasmic encephalitis in patients with AIDS. Italian Collaborative Study Group. ( Angarano, G; Carosi, G; Casari, S; Chiodo, F; Donisi, A; Fiori, G; Gregis, G; Orani, A; Poggio, A; Ranieri, S; Speranza, F; Torre, D, 1998) |
| "Between February 1990 and June 1993, 105 patients with HIV infection were enrolled after each had had resolution of an acute episode of toxoplasmic encephalitis treated with sulfadiazine (1 g four times per day) plus pyrimethamine (50 mg/d) plus folinic acid (15 mg/d) for 4 to 8 weeks." | 9.08 | Twice-weekly maintenance therapy with sulfadiazine-pyrimethamine to prevent recurrent toxoplasmic encephalitis in patients with AIDS. Spanish Toxoplasmosis Study Group. ( Bolao, F; Cosín, J; Domingo, P; Gatell, JM; Laguna, F; Miró, JM; Podzamczer, D; Santamaría, J; Sirera, G; Verdejo, J, 1995) |
| "Sixty-five patients intolerant of conventional toxoplasmic encephalitis therapies-pyrimethamine, sulphadiazine or clindamycin-received atovaquone as maintenance therapy after resolution of an acute episode of toxoplasmic encephalitis." | 9.08 | Atovaquone as long-term suppressive therapy for toxoplasmic encephalitis in patients with AIDS and multiple drug intolerance. Atovaquone Expanded Access Group. ( Gourdon, D; Katlama, C; Lapierre, D; Mouthon, B; Rousseau, F, 1996) |
| "Pyrimethamine (50 mg) with folinic acid (15 mg) given three times weekly was assessed as primary prophylaxis for toxoplasmic encephalitis (TE) in 554 human immunodeficiency virus-infected patients seropositive for Toxoplasma gondii and with < 200 CD4 cells/mm3." | 9.08 | Pyrimethamine for primary prophylaxis of toxoplasmic encephalitis in patients with human immunodeficiency virus infection: a double-blind, randomized trial. ANRS 005-ACTG 154 Group Members. Agence Nationale de Recherche sur le SIDA. AIDS Clinical Trial Gr ( Aubertin, J; Chêne, G; Hafner, R; Leport, C; Luft, BJ; Miro, J; Morlat, P; Pueyo, S; Rousseau, F; Salamon, R; Vildé, JL, 1996) |
| "This European multicenter study compares the efficacy and tolerance of the combination of pyrimethamine-clindamycin (Pyr-Cm) with the standard therapy pyrimethamine-sulfadiazine (Pyr-Sdz) for the treatment of toxoplasmic encephalitis (TE) in patients with AIDS." | 9.08 | Pyrimethamine-clindamycin vs. pyrimethamine-sulfadiazine as acute and long-term therapy for toxoplasmic encephalitis in patients with AIDS. ( Clumeck, N; De Wit, S; Katlama, C; O'Doherty, E; Van Glabeke, M, 1996) |
| "A double-blind, placebo-controlled trial was set up to compare clindamycin and pyrimethamine as prophylaxis for toxoplasmic encephalitis (TE) in HIV-infected patients at risk of the disorder." | 9.07 | Toxicity of clindamycin as prophylaxis for AIDS-associated toxoplasmic encephalitis. Community Programs for Clinical Research on AIDS. ( Besch, CL; Child, C; Deyton, L; Hafner, R; Jacobson, MA; Matts, JP; Muth, K; Wentworth, DN, 1992) |
| "A prospective study was conducted to evaluate azithromycin in combination with pyrimethamine for treatment of acute Toxoplasma encephalitis in patients with AIDS." | 9.07 | Pyrimethamine plus azithromycin for treatment of acute toxoplasmic encephalitis in patients with AIDS. ( Hazebroucq, V; Joly, V; Leport, C; Morlat, P; Raffi, F; Saba, J; Vildé, JL, 1993) |
| "To compare pyrimethamine plus clindamycin (PC) to pyrimethamine plus sulfadiazine (PS) as a treatment for toxoplasmic encephalitis (TE) in patients with the acquired immunodeficiency syndrome (AIDS)." | 9.07 | Treatment of toxoplasmic encephalitis in patients with AIDS. A randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazine. The California Collaborative Treatment Group. ( Antoniskis, D; Chiu, J; Clumeck, N; Dannemann, B; Israelski, D; Leport, C; Luft, B; McCutchan, JA; Morlat, P; Nussbaum, J, 1992) |
| "The interim results are presented of an ongoing large-scale, prospective, randomized study to determine the potential role of clindamycin in the treatment of toxoplasmic encephalitis." | 9.07 | Treatment of acute toxoplasmosis with intravenous clindamycin. The California Collaborative Treatment Group. ( Antoniskis, D; Chiu, J; Dannemann, BR; Israelski, DM; Leport, C; Luft, BJ; McCutchan, JA; Nussbaum, JN; Orellana, M; Vildé, JL, 1991) |
| "Prophylaxis of toxoplasmic encephalitis was performed with pyrimethamine in 6 patients with advanced HIV infection during combination therapy with protease inhibitors." | 7.72 | Drug monitoring of pyrimethamine during maintenance therapy of toxoplasmic encephalitis in patients with advanced HIV infection during HAART. ( Klinker, H; Langmann, P; Schirmer, D; Zilly, M, 2004) |
| "To evaluate the safety and efficacy of a fixed 25mg pyrimethamine--500mg sulfadoxine combination plus 15mg folinic acid given twice weekly for the prevention of relapses of Pneumocystis carinii pneumonia (PCP) and primary episodes of toxoplasmic encephalitis." | 7.71 | Twice-weekly pyrimethamine-sulfadoxine effectively prevents Pneumocystis carinii pneumonia relapse and toxoplasmic encephalitis in patients with AIDS. ( Albrecht, H; Behnsch, M; Bergmann, F; Grobusch, M; Grünewald, T; Padberg, J; Ruf, B; Schürmann, D; Suttorp, N; Vallée, M; Wünsche, T, 2001) |
| "The effectiveness of combinations of rifabutin with atovaquone, clindamycin, pyrimethamine, or sulfadiazine in the treatment of toxoplasmic encephalitis in a murine model was investigated." | 7.69 | Use of rifabutin in combination with atovaquone, clindamycin, pyrimethamine, or sulfadiazine for treatment of toxoplasmic encephalitis in mice. ( Araujo, FG; Remington, JS; Suzuki, Y, 1996) |
| "The incidence of Pneumocystis carinii pneumonia (PCP) and toxoplasmic encephalitis (TE) was analyzed in 83 human immunodeficiency virus (HIV)-infected patients who inhaled aerosolized pentamidine (AP) either for primary prophylaxis (group Ia) or secondary prophylaxis (group IIa) of PCP." | 7.68 | Prevention of Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus infected patients: a clinical approach comparing aerosolized pentamidine and pyrimethamine/sulfadoxine. ( Gottschalk, J; Grünewald, T; Jautzke, G; Köppen, S; Pohle, HD; Ruf, B, 1992) |
| "The efficacy and safety of 25 mg pyrimethamine plus 500 mg sulfadoxine given twice a week in preventing relapses of AIDS-related toxoplasmic encephalitis was evaluated in an open study." | 7.68 | Efficacy of pyrimethamine/sulfadoxine in the prevention of toxoplasmic encephalitis relapses and Pneumocystis carinii pneumonia in HIV-infected patients. ( Bergmann, F; Gottschalk, HJ; Grünewald, T; Pohle, HD; Ruf, B; Schüler-Maué, W; Schürmann, D; Witt, H, 1993) |
| "Fourteen patients with AIDS and toxoplasmic encephalitis, who could not be treated with the standard regimen of pyrimethamine and a sulfonamide due to a previous history of bone marrow suppression and severe allergic reactions to sulfonamides, were treated with oral clindamycin and pyrimethamine." | 7.68 | A retrospective study of primary and maintenance therapy of toxoplasmic encephalitis with oral clindamycin and pyrimethamine. ( Bini, T; Esposito, R; Foppa, CU; Gregis, G; Lazzarin, A; Moroni, M, 1991) |
| "Toxoplasma gondii encephalitis is an important opportunistic infection in the acquired immunodeficiency syndrome, estimated to occur in 20,000 to 40,000 patients with acquired immunodeficiency syndrome in the United States by 1991." | 6.38 | Sulfadiazine crystalluria revisited. The treatment of Toxoplasma encephalitis in patients with acquired immunodeficiency syndrome. ( Brosius, FC; Rothstein, DM; Simon, DI, 1990) |
| "In this international, noncomparative, randomized phase II trial, we evaluated the effectiveness and tolerance of atovaquone suspension (1500 mg orally twice daily) plus either pyrimethamine (75 mg per day after a 200-mg loading dose) or sulfadiazine (1500 mg 4 times daily) as treatment for acute disease (for 6 weeks) and as maintenance therapy (for 42 weeks) for toxoplasmic encephalitis (TE) in patients infected with human immunodeficiency virus." | 5.10 | Randomized phase II trial of atovaquone with pyrimethamine or sulfadiazine for treatment of toxoplasmic encephalitis in patients with acquired immunodeficiency syndrome: ACTG 237/ANRS 039 Study. AIDS Clinical Trials Group 237/Agence Nationale de Recherche ( Andersen, J; Bosler, EM; Chirgwin, K; Hafner, R; Jayaweera, DT; Leport, C; Luft, BJ; McAuliffe, V; Morlat, P; Rajicic, N; Remington, J; Roque, C; Vilde, JL, 2002) |
| "To assess the safety, tolerance and activity of increasing doses of azithromycin in combination with pyrimethamine for the treatment of toxoplasmic encephalitis (TE) in patients with AIDS." | 5.09 | Dose-escalation, phase I/II study of azithromycin and pyrimethamine for the treatment of toxoplasmic encephalitis in AIDS. ( Bosler, EM; Farthing, C; Hafner, R; Harris, C; Holden-Wiltse, J; Jacobson, JM; Jayaweera, DT; Luft, BJ; Remington, J; Roque, C, 2001) |
| "We assessed the incidence and determinants of bacteremia, pneumonia, and sinusitis/otitis in HIV-positive people receiving cotrimoxazole (CTX) or dapsone-pyrimethamine (DP) for primary prophylaxis of Pneumocystis carinii pneumonia (PCP) and toxoplasmic encephalitis (TE) within a randomized clinical trial." | 5.09 | Incidence and determinants of bacterial infections in HIV-positive patients receiving anti-Pneumocystis carinii/Toxoplasma gondii primary prophylaxis within a randomized clinical trial. ( Ammassari, A; Antinori, A; Cingolani, A; De Luca, A; Grillo, R; Murri, R; Pallavicini, F; Pezzotti, P, 2001) |
| "An open, randomised, multicentre trial was conducted to evaluate the efficacy of thrice-weekly versus daily therapy with sulfadiazine-pyrimethamine in the prevention of relapses of toxoplasmic encephalitis in HIV-infected patients." | 5.09 | Thrice-weekly sulfadiazine-pyrimethamine for maintenance therapy of toxoplasmic encephalitis in HIV-infected patients. Spanish Toxoplasmosis Study Group. ( Arrizabalaga, J; Cosin, J; Cruceta, A; Domingo, P; Fariñas, MC; Ferrer, E; Gatell, JM; Gudiol, F; Knobel, H; Leyes, M; Martínez-Lacasa, J; Miró, JM; Podzamczer, D; Polo, R; Ramón, JM; Ribera, E; Sirera, G, 2000) |
| "The aim of the present pilot study was to compare the efficacy and safety of trimethoprim (TMP) and sulfamethoxazole (SMX) with those of the standard therapy pyrimethamine (P)-sulfadiazine (S) for the treatment of toxoplasmic encephalitis in patients with AIDS." | 5.08 | Randomized trial of trimethoprim-sulfamethoxazole versus pyrimethamine-sulfadiazine for therapy of toxoplasmic encephalitis in patients with AIDS. Italian Collaborative Study Group. ( Angarano, G; Carosi, G; Casari, S; Chiodo, F; Donisi, A; Fiori, G; Gregis, G; Orani, A; Poggio, A; Ranieri, S; Speranza, F; Torre, D, 1998) |
| "Pyrimethamine (50 mg) with folinic acid (15 mg) given three times weekly was assessed as primary prophylaxis for toxoplasmic encephalitis (TE) in 554 human immunodeficiency virus-infected patients seropositive for Toxoplasma gondii and with < 200 CD4 cells/mm3." | 5.08 | Pyrimethamine for primary prophylaxis of toxoplasmic encephalitis in patients with human immunodeficiency virus infection: a double-blind, randomized trial. ANRS 005-ACTG 154 Group Members. Agence Nationale de Recherche sur le SIDA. AIDS Clinical Trial Gr ( Aubertin, J; Chêne, G; Hafner, R; Leport, C; Luft, BJ; Miro, J; Morlat, P; Pueyo, S; Rousseau, F; Salamon, R; Vildé, JL, 1996) |
| "Between February 1990 and June 1993, 105 patients with HIV infection were enrolled after each had had resolution of an acute episode of toxoplasmic encephalitis treated with sulfadiazine (1 g four times per day) plus pyrimethamine (50 mg/d) plus folinic acid (15 mg/d) for 4 to 8 weeks." | 5.08 | Twice-weekly maintenance therapy with sulfadiazine-pyrimethamine to prevent recurrent toxoplasmic encephalitis in patients with AIDS. Spanish Toxoplasmosis Study Group. ( Bolao, F; Cosín, J; Domingo, P; Gatell, JM; Laguna, F; Miró, JM; Podzamczer, D; Santamaría, J; Sirera, G; Verdejo, J, 1995) |
| "To evaluate combined prophylaxis for Pneumocystis carinii pneumonia (PCP) and toxoplasmic encephalitis, 533 patients with symptomatic human immunodeficiency virus infection and/or CD4 lymphocyte counts of < 200/microL were randomized to receive dapsone/pyrimethamine (200/75 mg once weekly) or aerosolized pentamidine (300 mg every 4 weeks)." | 5.08 | Once-weekly administration of dapsone/pyrimethamine vs. aerosolized pentamidine as combined prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus-infected patients. ( Heald, A; Hirschel, B; Iten, A; Lazzarin, A; Oertle, D; Opravil, M; Pechère, M; Praz, G; Rüttimann, S; von Overbeck, J, 1995) |
| "This European multicenter study compares the efficacy and tolerance of the combination of pyrimethamine-clindamycin (Pyr-Cm) with the standard therapy pyrimethamine-sulfadiazine (Pyr-Sdz) for the treatment of toxoplasmic encephalitis (TE) in patients with AIDS." | 5.08 | Pyrimethamine-clindamycin vs. pyrimethamine-sulfadiazine as acute and long-term therapy for toxoplasmic encephalitis in patients with AIDS. ( Clumeck, N; De Wit, S; Katlama, C; O'Doherty, E; Van Glabeke, M, 1996) |
| "Sixty-five patients intolerant of conventional toxoplasmic encephalitis therapies-pyrimethamine, sulphadiazine or clindamycin-received atovaquone as maintenance therapy after resolution of an acute episode of toxoplasmic encephalitis." | 5.08 | Atovaquone as long-term suppressive therapy for toxoplasmic encephalitis in patients with AIDS and multiple drug intolerance. Atovaquone Expanded Access Group. ( Gourdon, D; Katlama, C; Lapierre, D; Mouthon, B; Rousseau, F, 1996) |
| "A quantifiable neurologic assessment was used prospectively to evaluate the clinical outcome of patients with AIDS and toxoplasmic encephalitis who were treated with oral clindamycin (600 mg four times a day) and pyrimethamine (75 mg every day) for six weeks." | 5.07 | Toxoplasmic encephalitis in patients with the acquired immunodeficiency syndrome. Members of the ACTG 077p/ANRS 009 Study Team. ( Antoniskis, D; Bosler, EM; Bourland, DD; Fuhrer, J; Hafner, R; Jacobson, J; Korzun, AH; Leport, C; Luft, BJ; Uttamchandani, R, 1993) |
| "A double-blind, placebo-controlled trial was set up to compare clindamycin and pyrimethamine as prophylaxis for toxoplasmic encephalitis (TE) in HIV-infected patients at risk of the disorder." | 5.07 | Toxicity of clindamycin as prophylaxis for AIDS-associated toxoplasmic encephalitis. Community Programs for Clinical Research on AIDS. ( Besch, CL; Child, C; Deyton, L; Hafner, R; Jacobson, MA; Matts, JP; Muth, K; Wentworth, DN, 1992) |
| "A prospective study was conducted to evaluate azithromycin in combination with pyrimethamine for treatment of acute Toxoplasma encephalitis in patients with AIDS." | 5.07 | Pyrimethamine plus azithromycin for treatment of acute toxoplasmic encephalitis in patients with AIDS. ( Hazebroucq, V; Joly, V; Leport, C; Morlat, P; Raffi, F; Saba, J; Vildé, JL, 1993) |
| "The interim results are presented of an ongoing large-scale, prospective, randomized study to determine the potential role of clindamycin in the treatment of toxoplasmic encephalitis." | 5.07 | Treatment of acute toxoplasmosis with intravenous clindamycin. The California Collaborative Treatment Group. ( Antoniskis, D; Chiu, J; Dannemann, BR; Israelski, DM; Leport, C; Luft, BJ; McCutchan, JA; Nussbaum, JN; Orellana, M; Vildé, JL, 1991) |
| "To compare pyrimethamine plus clindamycin (PC) to pyrimethamine plus sulfadiazine (PS) as a treatment for toxoplasmic encephalitis (TE) in patients with the acquired immunodeficiency syndrome (AIDS)." | 5.07 | Treatment of toxoplasmic encephalitis in patients with AIDS. A randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazine. The California Collaborative Treatment Group. ( Antoniskis, D; Chiu, J; Clumeck, N; Dannemann, B; Israelski, D; Leport, C; Luft, B; McCutchan, JA; Morlat, P; Nussbaum, J, 1992) |
| "In a meta-analysis, we examined the efficacy of aerosolized pentamidine, trimethoprim-sulfamethoxazole, and dapsone or dapsone/pyrimethamine for the prevention of Pneumocystis carinii pneumonia and toxoplasma encephalitis in patients with HIV infection." | 4.79 | Meta-analysis of prophylactic treatments against Pneumocystis carinii pneumonia and toxoplasma encephalitis in HIV-infected patients. ( Bucher, HC; Griffith, L; Guyatt, GH; Opravil, M, 1997) |
| "Although the price increase of pyrimethamine in 2015 received heavy media coverage, there are little data regarding specific implications to hospitals and the total costs of treating inpatients with toxoplasmosis encephalitis (TE)." | 4.12 | Brief Report: Financial Burden of Toxoplasmosis Encephalitis Treatment at a Safety Net Hospital. ( Bogard, SN; Kempker, RR; Lee, JT; Patel, M, 2022) |
| "Prophylaxis of toxoplasmic encephalitis was performed with pyrimethamine in 6 patients with advanced HIV infection during combination therapy with protease inhibitors." | 3.72 | Drug monitoring of pyrimethamine during maintenance therapy of toxoplasmic encephalitis in patients with advanced HIV infection during HAART. ( Klinker, H; Langmann, P; Schirmer, D; Zilly, M, 2004) |
| "To evaluate the safety and efficacy of a fixed 25mg pyrimethamine--500mg sulfadoxine combination plus 15mg folinic acid given twice weekly for the prevention of relapses of Pneumocystis carinii pneumonia (PCP) and primary episodes of toxoplasmic encephalitis." | 3.71 | Twice-weekly pyrimethamine-sulfadoxine effectively prevents Pneumocystis carinii pneumonia relapse and toxoplasmic encephalitis in patients with AIDS. ( Albrecht, H; Behnsch, M; Bergmann, F; Grobusch, M; Grünewald, T; Padberg, J; Ruf, B; Schürmann, D; Suttorp, N; Vallée, M; Wünsche, T, 2001) |
| "In 26 AIDS patients treated for toxoplasmic encephalitis, the inhibitory effect on Toxoxplasma growth of sequential sera taken before and after initiation of therapy was determined using a culture-based immunoassay and compared with pyrimethamine blood levels." | 3.70 | Determination of the inhibitory effect on Toxoplasma growth in the serum of AIDS patients during acute therapy for toxoplasmic encephalitis. ( Derouin, F; Farinotti, R; Gérard, L; Leport, C; Maslo, C, 1998) |
| "A proportion of patients with AIDS and toxoplasmic encephalitis (TE) sustain low plasma pyrimethamine concentrations during oral treatment, possibly because of incomplete and variable bioavailability." | 3.70 | Disposition of intravenous pyrimethamine in healthy volunteers. ( Almond, DS; Edwards, G; Lee, MG; Szwandt, IS; Winstanley, PA, 2000) |
| " We illustrate all of our comparisons with a dataset from an AIDS clinical trial that compared the effectiveness of the drug pyrimethamine and a placebo in preventing toxoplasmic encephalitis." | 3.69 | Robust Bayesian approaches for clinical trial monitoring. ( Carlin, BP; Sargent, DJ, 1996) |
| "The effectiveness of combinations of rifabutin with atovaquone, clindamycin, pyrimethamine, or sulfadiazine in the treatment of toxoplasmic encephalitis in a murine model was investigated." | 3.69 | Use of rifabutin in combination with atovaquone, clindamycin, pyrimethamine, or sulfadiazine for treatment of toxoplasmic encephalitis in mice. ( Araujo, FG; Remington, JS; Suzuki, Y, 1996) |
| "The efficacy and safety of 25 mg pyrimethamine plus 500 mg sulfadoxine given twice a week in preventing relapses of AIDS-related toxoplasmic encephalitis was evaluated in an open study." | 3.68 | Efficacy of pyrimethamine/sulfadoxine in the prevention of toxoplasmic encephalitis relapses and Pneumocystis carinii pneumonia in HIV-infected patients. ( Bergmann, F; Gottschalk, HJ; Grünewald, T; Pohle, HD; Ruf, B; Schüler-Maué, W; Schürmann, D; Witt, H, 1993) |
| "Fourteen patients with AIDS and toxoplasmic encephalitis, who could not be treated with the standard regimen of pyrimethamine and a sulfonamide due to a previous history of bone marrow suppression and severe allergic reactions to sulfonamides, were treated with oral clindamycin and pyrimethamine." | 3.68 | A retrospective study of primary and maintenance therapy of toxoplasmic encephalitis with oral clindamycin and pyrimethamine. ( Bini, T; Esposito, R; Foppa, CU; Gregis, G; Lazzarin, A; Moroni, M, 1991) |
| "The incidence of Pneumocystis carinii pneumonia (PCP) and toxoplasmic encephalitis (TE) was analyzed in 83 human immunodeficiency virus (HIV)-infected patients who inhaled aerosolized pentamidine (AP) either for primary prophylaxis (group Ia) or secondary prophylaxis (group IIa) of PCP." | 3.68 | Prevention of Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus infected patients: a clinical approach comparing aerosolized pentamidine and pyrimethamine/sulfadoxine. ( Gottschalk, J; Grünewald, T; Jautzke, G; Köppen, S; Pohle, HD; Ruf, B, 1992) |
| " The weekly dosage of pyrimethamine ranged from 25 to 1,400 mg; one patient with severe diarrhea received 2,100 mg/week." | 2.68 | Plasma pyrimethamine concentrations during long-term treatment for cerebral toxoplasmosis in patients with AIDS. ( Klinker, H; Langmann, P; Richter, E, 1996) |
| "Toxoplasma gondii encephalitis is an important opportunistic infection in the acquired immunodeficiency syndrome, estimated to occur in 20,000 to 40,000 patients with acquired immunodeficiency syndrome in the United States by 1991." | 2.38 | Sulfadiazine crystalluria revisited. The treatment of Toxoplasma encephalitis in patients with acquired immunodeficiency syndrome. ( Brosius, FC; Rothstein, DM; Simon, DI, 1990) |
| "Toxoplasmosis is usually an asymptomatic infection, but symptomatic cases are becoming more common with the rise in AIDS cases and the increased number of patients receiving immunosuppressive therapy." | 1.27 | Toxoplasmosis of the central nervous system. ( Meredith, JT, 1987) |
| "Toxoplasma encephalitis has been reported as a life-threatening opportunistic infection among patients with the acquired immune deficiency syndrome." | 1.27 | Assessment of therapy for toxoplasma encephalitis. The TE Study Group. ( Haverkos, HW, 1987) |
| "Toxoplasma encephalitis has a high mortality, and active treatment is recommended." | 1.27 | Acquired toxoplasma encephalitis. ( Cottrell, AJ, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 17 (23.94) | 18.7374 |
| 1990's | 42 (59.15) | 18.2507 |
| 2000's | 9 (12.68) | 29.6817 |
| 2010's | 1 (1.41) | 24.3611 |
| 2020's | 2 (2.82) | 2.80 |
| Authors | Studies |
|---|---|
| Prosty, C | 1 |
| Hanula, R | 1 |
| Levin, Y | 1 |
| Bogoch, II | 1 |
| McDonald, EG | 1 |
| Lee, TC | 1 |
| Bogard, SN | 1 |
| Lee, JT | 1 |
| Patel, M | 1 |
| Kempker, RR | 1 |
| Baliu, C | 1 |
| Sanclemente, G | 1 |
| Cardona, M | 1 |
| Castel, MA | 1 |
| Perez-Villa, F | 1 |
| Moreno, A | 1 |
| Cervera, C | 1 |
| Hill, D | 1 |
| Dubey, JP | 1 |
| STAHLIE, TD | 1 |
| Langmann, P | 2 |
| Schirmer, D | 1 |
| Zilly, M | 1 |
| Klinker, H | 2 |
| Filice, G | 1 |
| Carnevale, G | 1 |
| Orsolini, P | 1 |
| Soldini, L | 1 |
| Meroni, V | 1 |
| Comolli, G | 1 |
| Carenzo, L | 1 |
| Robinson, RO | 1 |
| Baumann, RJ | 1 |
| Katlama, C | 5 |
| Podzamczer, D | 2 |
| Miró, JM | 2 |
| Bolao, F | 1 |
| Gatell, JM | 2 |
| Cosín, J | 2 |
| Sirera, G | 2 |
| Domingo, P | 2 |
| Laguna, F | 1 |
| Santamaría, J | 1 |
| Verdejo, J | 1 |
| Kovacs, JA | 2 |
| Opravil, M | 2 |
| Hirschel, B | 2 |
| Lazzarin, A | 2 |
| Heald, A | 1 |
| Pechère, M | 1 |
| Rüttimann, S | 1 |
| Iten, A | 1 |
| von Overbeck, J | 1 |
| Oertle, D | 1 |
| Praz, G | 1 |
| Oksenhendler, E | 1 |
| Charreau, I | 1 |
| Tournerie, C | 2 |
| Azihary, M | 1 |
| Carbon, C | 1 |
| Aboulker, JP | 1 |
| Saba, J | 1 |
| Morlat, P | 6 |
| Raffi, F | 1 |
| Hazebroucq, V | 1 |
| Joly, V | 1 |
| Leport, C | 10 |
| Vildé, JL | 8 |
| McCabe, R | 1 |
| Chirurgi, V | 1 |
| Ruf, B | 3 |
| Schürmann, D | 2 |
| Bergmann, F | 2 |
| Schüler-Maué, W | 1 |
| Grünewald, T | 3 |
| Gottschalk, HJ | 1 |
| Witt, H | 1 |
| Pohle, HD | 2 |
| Luft, BJ | 9 |
| Hafner, R | 9 |
| Korzun, AH | 1 |
| Antoniskis, D | 3 |
| Bosler, EM | 3 |
| Bourland, DD | 1 |
| Uttamchandani, R | 1 |
| Fuhrer, J | 1 |
| Jacobson, J | 1 |
| Girard, PM | 1 |
| Landman, R | 1 |
| Gaudebout, C | 2 |
| Olivares, R | 1 |
| Saimot, AG | 1 |
| Jelazko, P | 1 |
| Certain, A | 1 |
| Boué, F | 1 |
| Bouvet, E | 1 |
| Caumes, E | 1 |
| Bocquet, H | 1 |
| Guermonprez, G | 1 |
| Rogeaux, O | 1 |
| Bricaire, F | 1 |
| Gentilini, M | 1 |
| Chêne, G | 3 |
| Rousseau, F | 3 |
| Pueyo, S | 3 |
| Miro, J | 2 |
| Aubertin, J | 3 |
| Salamon, R | 3 |
| Richards, FO | 1 |
| Antinori, A | 2 |
| Murri, R | 2 |
| Ammassari, A | 2 |
| De Luca, A | 2 |
| Linzalone, A | 1 |
| Cingolani, A | 2 |
| Damiano, F | 1 |
| Maiuro, G | 1 |
| Vecchiet, J | 1 |
| Scoppettuolo, G | 1 |
| Caramello, P | 1 |
| Brancale, T | 1 |
| Forno, B | 1 |
| Lucchini, A | 1 |
| Pollono, AM | 1 |
| Ullio, A | 1 |
| Gioannini, P | 1 |
| Viano, I | 1 |
| Tonso, E | 1 |
| Van Delden, C | 1 |
| Araujo, FG | 1 |
| Suzuki, Y | 1 |
| Remington, JS | 4 |
| Carlin, BP | 1 |
| Sargent, DJ | 1 |
| Richter, E | 1 |
| De Wit, S | 1 |
| O'Doherty, E | 1 |
| Van Glabeke, M | 1 |
| Clumeck, N | 2 |
| Mouthon, B | 1 |
| Gourdon, D | 1 |
| Lapierre, D | 1 |
| Derouin, F | 2 |
| Letrillart, B | 1 |
| Ecobichon, JL | 1 |
| Luft, B | 2 |
| Bucher, HC | 1 |
| Griffith, L | 1 |
| Guyatt, GH | 1 |
| Supiot, F | 1 |
| Guillaume, MP | 1 |
| Hermanus, N | 1 |
| Telerman-Toppet, N | 1 |
| Karmali, R | 1 |
| Torre, D | 1 |
| Casari, S | 1 |
| Speranza, F | 1 |
| Donisi, A | 1 |
| Gregis, G | 2 |
| Poggio, A | 1 |
| Ranieri, S | 1 |
| Orani, A | 1 |
| Angarano, G | 1 |
| Chiodo, F | 1 |
| Fiori, G | 1 |
| Carosi, G | 1 |
| Gérard, L | 1 |
| Farinotti, R | 1 |
| Maslo, C | 1 |
| Yoshimura, K | 1 |
| Hara, T | 1 |
| Tsurumi, H | 1 |
| Goto, H | 1 |
| Tajika, M | 1 |
| Fukutomi, Y | 1 |
| Murakami, N | 1 |
| Moriwaki, H | 1 |
| Ferrer, E | 1 |
| Ramón, JM | 1 |
| Ribera, E | 1 |
| Cruceta, A | 1 |
| Knobel, H | 1 |
| Polo, R | 1 |
| Leyes, M | 1 |
| Fariñas, MC | 1 |
| Arrizabalaga, J | 2 |
| Martínez-Lacasa, J | 1 |
| Gudiol, F | 1 |
| Almond, DS | 1 |
| Szwandt, IS | 1 |
| Edwards, G | 1 |
| Lee, MG | 1 |
| Winstanley, PA | 1 |
| Lacascade, C | 1 |
| Conge, AM | 1 |
| Baillat, V | 1 |
| Pages, I | 1 |
| Huguet, MF | 1 |
| Reynes, J | 1 |
| Vendrell, JP | 1 |
| Albrecht, H | 1 |
| Padberg, J | 1 |
| Behnsch, M | 1 |
| Grobusch, M | 1 |
| Vallée, M | 1 |
| Wünsche, T | 1 |
| Suttorp, N | 1 |
| Jacobson, JM | 1 |
| Remington, J | 2 |
| Farthing, C | 1 |
| Holden-Wiltse, J | 1 |
| Harris, C | 2 |
| Jayaweera, DT | 2 |
| Roque, C | 2 |
| Pezzotti, P | 1 |
| Pallavicini, F | 1 |
| Grillo, R | 1 |
| Kupila, L | 1 |
| Sonninen, V | 1 |
| Peltonen, R | 1 |
| Uksila, J | 1 |
| Hukkanen, V | 1 |
| Kotilainen, P | 1 |
| Chirgwin, K | 1 |
| Andersen, J | 1 |
| Rajicic, N | 1 |
| McAuliffe, V | 1 |
| Jacobson, MA | 2 |
| Besch, CL | 2 |
| Child, C | 2 |
| Matts, JP | 1 |
| Muth, K | 2 |
| Wentworth, DN | 1 |
| Deyton, L | 2 |
| Köppen, S | 1 |
| Jautzke, G | 1 |
| Gottschalk, J | 1 |
| Iribarren, JA | 1 |
| Garde, C | 1 |
| Rodriguez-Arrondo, F | 1 |
| Blanco, A | 1 |
| Dannemann, B | 1 |
| McCutchan, JA | 2 |
| Israelski, D | 1 |
| Nussbaum, J | 1 |
| Chiu, J | 2 |
| Foppa, CU | 1 |
| Bini, T | 1 |
| Esposito, R | 1 |
| Moroni, M | 1 |
| Raguin, G | 1 |
| Fernandez-Martin, J | 1 |
| Niyongabo, T | 1 |
| Dannemann, BR | 2 |
| Israelski, DM | 1 |
| Nussbaum, JN | 1 |
| Orellana, M | 1 |
| Simon, DI | 1 |
| Brosius, FC | 1 |
| Rothstein, DM | 1 |
| Carrazana, EJ | 1 |
| Rossitch, E | 1 |
| Samuels, MA | 1 |
| Cohn, JA | 1 |
| McMeeking, A | 1 |
| Cohen, W | 1 |
| Jacobs, J | 1 |
| Holzman, RS | 1 |
| Weiss, LM | 1 |
| Berger, M | 1 |
| Tanowitz, HB | 1 |
| Wittner, M | 1 |
| Wanke, C | 1 |
| Tuazon, CU | 1 |
| Kovacs, A | 1 |
| Dina, T | 1 |
| Davis, DO | 1 |
| Barton, N | 1 |
| Katz, D | 1 |
| Lunde, M | 1 |
| Levy, C | 1 |
| Conley, FK | 1 |
| Lim, BT | 1 |
| Carbaat, PA | 1 |
| van Knapen, F | 1 |
| Meredith, JT | 1 |
| Haverkos, HW | 1 |
| Cottrell, AJ | 1 |
| Payet, M | 1 |
| Coulaud, JP | 1 |
| Pasticier, A | 1 |
| Saimot, G | 1 |
| Fanghänel, M | 1 |
| Meyfarth, G | 1 |
| Molkentin, K | 1 |
| Rieder, RT | 1 |
| Granz, W | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Dose-Escalation, Phase I/II Study of Oral Azithromycin and Pyrimethamine for the Treatment of Toxoplasmic Encephalitis in Patients With AIDS[NCT00000966] | Phase 1 | 45 participants | Interventional | Completed | |||
| A Pilot Study of Oral Clindamycin and Pyrimethamine for the Treatment of Toxoplasmic Encephalitis in Patients With AIDS[NCT00000674] | 30 participants | Interventional | Completed | ||||
| Primary Prophylaxis of Cerebral Toxoplasmosis in HIV-Infected Patients[NCT00000643] | Phase 2 | 150 participants | Interventional | Completed | |||
| Phase II Randomized Open-Label Trial of Atovaquone Plus Pyrimethamine and Atovaquone Plus Sulfadiazine for the Treatment of Acute Toxoplasmic Encephalitis[NCT00000794] | Phase 2 | 100 participants | Interventional | Completed | |||
| A Randomized Prospective Study of Pyrimethamine Therapy for Prevention of Toxoplasmic Encephalitis in HIV-Infected Individuals With Serologic Evidence of Latent Toxoplasma Gondii Infection[NCT00000666] | 600 participants | Interventional | Completed | ||||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 reviews available for pyrimethamine and Brain Inflammation
| Article | Year |
|---|---|
Revisiting the Evidence Base for Modern-Day Practice of the Treatment of Toxoplasmic Encephalitis: A Systematic Review and Meta-Analysis.
Topics: Encephalitis; HIV Infections; Humans; Pyrimethamine; Toxoplasmosis, Cerebral; Trimethoprim, Sulfamet | 2023 |
Toxoplasma gondii: transmission, diagnosis and prevention.
Topics: Acquired Immunodeficiency Syndrome; Animals; Antibodies, Protozoan; Cats; Cattle; Deer; Encephalitis | 2002 |
Issues in toxoplasmosis.
Topics: AIDS-Related Opportunistic Infections; Animals; Clindamycin; Drug Therapy, Combination; Encephalitis | 1993 |
Preventing toxoplasmic encephalitis in persons infected with human immunodeficiency virus.
Topics: AIDS-Related Opportunistic Infections; Animals; Anti-Infective Agents; Cats; Dapsone; Drug Therapy, | 1995 |
Meta-analysis of prophylactic treatments against Pneumocystis carinii pneumonia and toxoplasma encephalitis in HIV-infected patients.
Topics: Administration, Inhalation; AIDS-Related Opportunistic Infections; Anti-Infective Agents; Antifungal | 1997 |
Sulfadiazine crystalluria revisited. The treatment of Toxoplasma encephalitis in patients with acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Acute Kidney Injury; Adult; Crystallization; Drug Therapy, Combi | 1990 |
AIDS commentary. Toxoplasmic encephalitis.
Topics: Acquired Immunodeficiency Syndrome; Animals; Anti-Bacterial Agents; Antibodies, Protozoan; Antimetab | 1988 |
22 trials available for pyrimethamine and Brain Inflammation
| Article | Year |
|---|---|
Twice-weekly maintenance therapy with sulfadiazine-pyrimethamine to prevent recurrent toxoplasmic encephalitis in patients with AIDS. Spanish Toxoplasmosis Study Group.
Topics: Adult; Aged; AIDS-Related Opportunistic Infections; Drug Administration Schedule; Drug Therapy, Comb | 1995 |
Once-weekly administration of dapsone/pyrimethamine vs. aerosolized pentamidine as combined prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus-infected patients.
Topics: Administration, Inhalation; Adult; AIDS-Related Opportunistic Infections; Animals; Dapsone; Drug Adm | 1995 |
Pyrimethamine plus azithromycin for treatment of acute toxoplasmic encephalitis in patients with AIDS.
Topics: Acute Disease; Adult; AIDS-Related Opportunistic Infections; Azithromycin; Drug Administration Sched | 1993 |
Toxoplasmic encephalitis in patients with the acquired immunodeficiency syndrome. Members of the ACTG 077p/ANRS 009 Study Team.
Topics: Acute Disease; Adult; AIDS-Related Opportunistic Infections; Clindamycin; Encephalitis; Female; Huma | 1993 |
Dapsone-pyrimethamine compared with aerosolized pentamidine as primary prophylaxis against Pneumocystis carinii pneumonia and toxoplasmosis in HIV infection. The PRIO Study Group.
Topics: Adult; AIDS-Related Complex; AIDS-Related Opportunistic Infections; Dapsone; Drug Combinations; Ence | 1993 |
Pyrimethamine for primary prophylaxis of toxoplasmic encephalitis in patients with human immunodeficiency virus infection: a double-blind, randomized trial. ANRS 005-ACTG 154 Group Members. Agence Nationale de Recherche sur le SIDA. AIDS Clinical Trial Gr
Topics: Adult; AIDS-Related Opportunistic Infections; Animals; Anti-Infective Agents; Antibodies, Protozoan; | 1996 |
Aerosolized pentamidine, cotrimoxazole and dapsone-pyrimethamine for primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Animals; Anti-Infe | 1995 |
Plasma pyrimethamine concentrations during long-term treatment for cerebral toxoplasmosis in patients with AIDS.
Topics: AIDS-Related Opportunistic Infections; Dose-Response Relationship, Drug; Encephalitis; Humans; Pyrim | 1996 |
Pyrimethamine-clindamycin vs. pyrimethamine-sulfadiazine as acute and long-term therapy for toxoplasmic encephalitis in patients with AIDS.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Infective Agents; Clindamycin; Drug Therapy, Comb | 1996 |
Atovaquone as long-term suppressive therapy for toxoplasmic encephalitis in patients with AIDS and multiple drug intolerance. Atovaquone Expanded Access Group.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiprotozoal Agents; Atovaquone; Clindamycin; Encephalit | 1996 |
Increased risk of toxoplasmic encephalitis in human immunodeficiency virus-infected patients with pyrimethamine-related rash. ANRS 005-ACTG 154 Trial Group. Agence Nationale de Recherche sur le SIDA (ANRS-INSERM) and the NIAID-AIDS Clinical Trials Group.
Topics: AIDS-Related Opportunistic Infections; Antiprotozoal Agents; Disease Progression; Double-Blind Metho | 1997 |
Randomized trial of trimethoprim-sulfamethoxazole versus pyrimethamine-sulfadiazine for therapy of toxoplasmic encephalitis in patients with AIDS. Italian Collaborative Study Group.
Topics: Adult; AIDS-Related Opportunistic Infections; Animals; Anti-Infective Agents; Encephalitis; Female; | 1998 |
Thrice-weekly sulfadiazine-pyrimethamine for maintenance therapy of toxoplasmic encephalitis in HIV-infected patients. Spanish Toxoplasmosis Study Group.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiprotozoal Agents; Drug Therapy, Combination; Encep | 2000 |
Dose-escalation, phase I/II study of azithromycin and pyrimethamine for the treatment of toxoplasmic encephalitis in AIDS.
Topics: Adult; AIDS-Related Opportunistic Infections; Animals; Anti-Bacterial Agents; Antiprotozoal Agents; | 2001 |
TMP-SMX superior in treating Toxoplasma encephalitis.
Topics: Anti-Infective Agents; Encephalitis; Humans; Pyrimethamine; Randomized Controlled Trials as Topic; S | 1997 |
Incidence and determinants of bacterial infections in HIV-positive patients receiving anti-Pneumocystis carinii/Toxoplasma gondii primary prophylaxis within a randomized clinical trial.
Topics: Adult; Animals; Anti-Infective Agents; Bacterial Infections; Dapsone; Encephalitis; Female; HIV Infe | 2001 |
Randomized phase II trial of atovaquone with pyrimethamine or sulfadiazine for treatment of toxoplasmic encephalitis in patients with acquired immunodeficiency syndrome: ACTG 237/ANRS 039 Study. AIDS Clinical Trials Group 237/Agence Nationale de Recherche
Topics: Acquired Immunodeficiency Syndrome; Acute Disease; Adult; AIDS-Related Opportunistic Infections; Ani | 2002 |
Toxicity of clindamycin as prophylaxis for AIDS-associated toxoplasmic encephalitis. Community Programs for Clinical Research on AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Animals; Clindamycin; Double-Blind Method; Encephalitis; | 1992 |
Clinical programs for clinical research on AIDS: description of a randomized prospective study of clindamycin versus pyrimethamine for prevention of Toxoplasma gondii infection.
Topics: Acquired Immunodeficiency Syndrome; CD4-Positive T-Lymphocytes; Clindamycin; Encephalitis; Humans; L | 1991 |
Treatment of toxoplasmic encephalitis in patients with AIDS. A randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazine. The California Collaborative Treatment Group.
Topics: Acquired Immunodeficiency Syndrome; Adult; Clindamycin; Drug Evaluation; Drug Therapy, Combination; | 1992 |
Evaluation of the efficacy and safety of clindamycin plus pyrimethamine for induction and maintenance therapy of toxoplasmic encephalitis in AIDS.
Topics: Acquired Immunodeficiency Syndrome; Clindamycin; Drug Therapy, Combination; Encephalitis; Humans; Op | 1991 |
Treatment of acute toxoplasmosis with intravenous clindamycin. The California Collaborative Treatment Group.
Topics: Acquired Immunodeficiency Syndrome; Clindamycin; Drug Therapy, Combination; Encephalitis; Humans; In | 1991 |
42 other studies available for pyrimethamine and Brain Inflammation
| Article | Year |
|---|---|
Brief Report: Financial Burden of Toxoplasmosis Encephalitis Treatment at a Safety Net Hospital.
Topics: Encephalitis; Financial Stress; HIV Infections; Humans; Pharmaceutical Preparations; Pyrimethamine; | 2022 |
Toxoplasmic encephalitis associated with meningitis in a heart transplant recipient.
Topics: Antiprotozoal Agents; Clindamycin; Drug Therapy, Combination; Encephalitis; Heart Transplantation; H | 2014 |
[SWOLLEN CERVICAL LYMPH GLANDS].
Topics: Child; Complement Fixation Tests; Diagnosis, Differential; Encephalitis; Exanthema; Hepatitis; Human | 1964 |
Drug monitoring of pyrimethamine during maintenance therapy of toxoplasmic encephalitis in patients with advanced HIV infection during HAART.
Topics: Adult; Age Factors; Antiretroviral Therapy, Highly Active; Chromatography, Gas; Chromatography, High | 2004 |
Chemotherapy of toxoplasmic encephalitis in AIDS patients.
Topics: Administration, Oral; AIDS-Related Opportunistic Infections; Antiprotozoal Agents; Encephalitis; Hum | 1989 |
Late cerebral relapse of congenital toxoplasmosis.
Topics: Child; Chorioretinitis; Drug Therapy, Combination; Encephalitis; Female; Humans; Pyrimethamine; Recu | 1980 |
[The impact of the prevention of cerebral toxoplasmosis].
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Infective Agents; Antiprotozoal Agents; Brain Abs | 1995 |
Toxoplasmosis in AIDS: keeping the lid on.
Topics: AIDS-Related Opportunistic Infections; Drug Therapy, Combination; Encephalitis; Humans; Pyrimethamin | 1995 |
Toxoplasma gondii infection in advanced HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Dapsone; Encephalitis; Female; Humans; Male; Middle Ag | 1994 |
Efficacy of pyrimethamine/sulfadoxine in the prevention of toxoplasmic encephalitis relapses and Pneumocystis carinii pneumonia in HIV-infected patients.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Infective Agents; Drug Administration Schedule; D | 1993 |
Adverse cutaneous reactions to pyrimethamine/sulfadiazine and pyrimethamine/clindamycin in patients with AIDS and toxoplasmic encephalitis.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Anti-Infective Agents; Clindamy | 1995 |
Relapse of Toxoplasma encephalitis and susceptibility to pyrimethamine: lack of evidence of treatment-induced resistance.
Topics: Adult; Anti-Infective Agents; Drug Resistance; Encephalitis; Humans; Pyrimethamine; Recurrence; Toxo | 1995 |
Folinic acid supplements to pyrimethamine-sulfadiazine for Toxoplasma encephalitis are associated with better outcome.
Topics: Antiprotozoal Agents; Drug Combinations; Drug Interactions; Drug Therapy, Combination; Encephalitis; | 1996 |
Use of rifabutin in combination with atovaquone, clindamycin, pyrimethamine, or sulfadiazine for treatment of toxoplasmic encephalitis in mice.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antiprotozoal Agents; Atovaquone; Brain; Clin | 1996 |
Robust Bayesian approaches for clinical trial monitoring.
Topics: AIDS-Related Opportunistic Infections; Anti-Infective Agents; Bayes Theorem; Controlled Clinical Tri | 1996 |
Predictive value of Toxoplasma gondii antibody titres on the occurrence of toxoplasmic encephalitis in HIV-infected patients. ANRS 005/ACTG 154 Trial Group.
Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Animals; Antibodies, Protozoan; Antiprotoz | 1996 |
Toxoplasma encephalitis in a HIV patient: unusual involvement of the corpus callosum.
Topics: Adult; Animals; Anti-Infective Agents; Brain Neoplasms; Corpus Callosum; Diagnosis, Differential; En | 1997 |
Determination of the inhibitory effect on Toxoplasma growth in the serum of AIDS patients during acute therapy for toxoplasmic encephalitis.
Topics: Acquired Immunodeficiency Syndrome; Adult; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Dr | 1998 |
[Non-Hodgkin's lymphoma with Toxoplasma encephalitis].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Antiprotozoal Agents; Cyclophosphamide; Dox | 1999 |
Disposition of intravenous pyrimethamine in healthy volunteers.
Topics: Acquired Immunodeficiency Syndrome; Antimalarials; Encephalitis; Humans; Infusions, Intravenous; Mal | 2000 |
In vitro anti-Toxoplasma gondii antibody production by peripheral blood mononuclear cells in the diagnosis and the monitoring of toxoplasmic encephalitis in AIDS-related brain lesions.
Topics: Adult; Aged; AIDS-Related Opportunistic Infections; Antibodies, Protozoan; Antiprotozoal Agents; Enc | 2000 |
Twice-weekly pyrimethamine-sulfadoxine effectively prevents Pneumocystis carinii pneumonia relapse and toxoplasmic encephalitis in patients with AIDS.
Topics: Adult; Aged; AIDS-Related Opportunistic Infections; Anti-Infective Agents; Cohort Studies; Drug Comb | 2001 |
[Toxoplasma encephalitis in a previously healthy man].
Topics: Abattoirs; Antiprotozoal Agents; Drug Therapy, Combination; Encephalitis; Humans; Male; Middle Aged; | 1999 |
Prevention of Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus infected patients: a clinical approach comparing aerosolized pentamidine and pyrimethamine/sulfadoxine.
Topics: Adult; Aerosols; Aged; CD4-Positive T-Lymphocytes; Drug Combinations; Encephalitis; Female; HIV Infe | 1992 |
Empiric treatment of acute Toxoplasma encephalitis in patients with acquired immunodeficiency syndrome.
Topics: AIDS-Related Opportunistic Infections; Encephalitis; Humans; Pyrimethamine; Sulfadiazine; Toxoplasmo | 1992 |
Clindamycin for toxoplasma encephalitis in AIDS.
Topics: Acquired Immunodeficiency Syndrome; Clindamycin; Drug Combinations; Encephalitis; Humans; Pyrimetham | 1991 |
A retrospective study of primary and maintenance therapy of toxoplasmic encephalitis with oral clindamycin and pyrimethamine.
Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Adult; Clindamycin; Drug Therapy, Combinat | 1991 |
Long-term follow-up of patients with AIDS on maintenance therapy for toxoplasmosis.
Topics: Acquired Immunodeficiency Syndrome; Clindamycin; Drug Therapy, Combination; Encephalitis; Follow-Up | 1991 |
Toxoplasmic encephalitis.
Topics: Acquired Immunodeficiency Syndrome; Drug Combinations; Encephalitis; Humans; Opportunistic Infection | 1990 |
Toxoplasmic encephalitis in AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Animals; Antibodies, Protozoan; Brain; Diagnosis, Differe | 1989 |
Cerebral toxoplasmosis in the acquired immune deficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Encephalitis; Female; Humans; Male; Middle Aged; Py | 1989 |
Evaluation of the policy of empiric treatment of suspected Toxoplasma encephalitis in patients with the acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Adult; Biopsy; Brain; Clindamycin; Encephalitis; Female; Humans; | 1989 |
Pyrimethamine concentrations in serum and cerebrospinal fluid during treatment of acute Toxoplasma encephalitis in patients with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Acute Disease; Encephalitis; Humans; Pyrimethamine; Toxoplasmosi | 1988 |
Toxoplasma encephalitis in patients with acquired immune deficiency syndrome: diagnosis and response to therapy.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antibodies; Drug Therapy, Combination; Encephalitis; Huma | 1987 |
[A young man with acute toxoplasmosis encephalitis].
Topics: Acute Disease; Adult; Drug Therapy, Combination; Encephalitis; Humans; Leucovorin; Male; Pyrimethami | 1987 |
Toxoplasmosis of the central nervous system.
Topics: Adult; Central Nervous System Diseases; Cerebellum; Encephalitis; Female; Humans; Pyrimethamine; Sul | 1987 |
Assessment of therapy for toxoplasma encephalitis. The TE Study Group.
Topics: Acquired Immunodeficiency Syndrome; Adrenal Cortex Hormones; Adult; Encephalitis; Evaluation Studies | 1987 |
Acquired toxoplasma encephalitis.
Topics: Child, Preschool; Drug Therapy, Combination; Encephalitis; Humans; Male; Pyrimethamine; Sulfamethazi | 1986 |
[Tropical and parasitic diseases].
Topics: Acute Kidney Injury; Amebiasis; Antimalarials; Cholera; Drug Resistance, Microbial; Encephalitis; Gl | 1974 |
[Congenital toxoplasmosis diagnosis, a cooperative effort of obstetrician and pediatrician].
Topics: Adult; Encephalitis; Female; Humans; Infant, Newborn; Pregnancy; Pyrimethamine; Serologic Tests; Ski | 1969 |
[Childhood toxoplasmosis in Schleswig].
Topics: Child; Child, Preschool; Encephalitis; Germany, West; Humans; Infant; Infant, Newborn; Infant, Newbo | 1970 |
[Acquired toxoplasmosis].
Topics: Animals; Complement Fixation Tests; Diagnosis, Differential; Encephalitis; Hemagglutination Tests; H | 1967 |